Holen Sie sich die Stockscreener-App
989.50
0.73%
-8.085
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Roll Tide: Lilly selects Alabama site as location for $6B API facility - Fierce Pharma
Pharmaceutical giant Eli Lilly expected to make “big announcement” during press conference in Huntsville - WAFF
Prediction: This Surprising Growth Stock Will Reach -- and Stay in -- the Trillion-Dollar Club in 2026. - The Motley Fool
Nobel Prize-Winning Chemist Carolyn Bertozzi Rejoins Eli Lilly’s (LLY) Board of Directors - TipRanks
Eli Lilly's (LLY) Orforglipron Compared to Pfizer's New Collaboration - GuruFocus
Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 - Oncodaily
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies - GuruFocus
Looking At Eli Lilly's Recent Unusual Options Activity - Benzinga
Eli Lilly's Flying Tigers Acquisition Completes Tender Offer for Adverum Shares - marketscreener.com
Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies - Nasdaq
Eli Lilly completes acquisition of Adverum Biotechnologies - Seeking Alpha
Lilly completes tender offer for Adverum Biotechnologies - Investing.com
Adverum Biotechnologies Stock (ADVM) Opinions on Lilly Acquisition - Quiver Quantitative
Eli Lilly (LLY) Achieves Key Milestone with Jaypirca in Phase 3 Trial - GuruFocus
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
How Lilly uses Big Pharma heft to lift up-and-coming biotechs - PharmaVoice
Eli Lilly and Company $LLY Shares Sold by Investment Management Corp of Ontario - MarketBeat
Eli Lilly's (LLY) Pirtobrutinib Shows Promising Results in Phase 3 Trial for CLL/SLL - GuruFocus
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - Yahoo Finance
Lilly’s Jaypirca reduces progression risk by 80% in untreated CLL - Investing.com
Lilly's Jaypirca succeeds in late-stage trial as a first-line option in lymphoma - Seeking Alpha
State Street Corp Purchases 69,018 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip? - MSN
Eli Lilly will be ‘aggressive’ in spending GLP-1 money, top dealmaker Van Naarden says - Endpoints News
The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In - Stocktwits
Daiwa Securities Group Inc. Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Fayez Sarofim & Co Sells 17,947 Shares of Eli Lilly and Company $LLY - MarketBeat
Axa S.A. Decreases Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Shares Navigate a Contradictory Market Phase - AD HOC NEWS
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Sen. John Boozman - MarketBeat
Carolyn Bertozzi returns to Eli Lilly board of directors - Medical Dialogues
8-Day Sell-Off Sends Eli Lilly Stock Down 10% - Trefis
Lilly Adopts ABL Bio's ‘BBB Shuttle’ to Tackle Alzheimer’s Treatment Challenges - Businesskorea
Eli Lilly (LLY): Reassessing Valuation After a Sharp Three-Month Rally and Brief Pullback - simplywall.st
Eli Lilly (LLY) Raises Dividend by 15% - TipRanks
Eli Lilly (LLY) Boosts Dividend by 15.3% - GuruFocus
Eli Lilly’s Mounjaro joins China’s health insurance scheme, challenging competitors - WISH-TV
Meds from Pfizer, Lilly, J&J and more secure spots in China's 1st private insurance formulary - Fierce Pharma
Eli Lilly declares Q1 2026 dividend of $1.73 per share - marketscreener.com
Lilly declares first-quarter 2026 dividend - Investing News Network
Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment - Reuters
Eli Lilly Raises Quarterly Dividend to $1.73 a Share From $1.50, Payable March 10 to Shareholders of Record on Feb. 13 - marketscreener.com
Eli Lilly's (LLY) Orforglipron Benchmark Surpassed by Competitor in Weight Loss Study - GuruFocus
Lilly declares first quarter 2026 dividend of $1.73 per share By Investing.com - Investing.com UK
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield - StreetInsider
Eli Lilly's Leukemia Drug Matches Johnson & Johnson's Imbruvica In Untreated Patients - Benzinga
Guggenheim maintains buy on Eli Lilly (LLY) after "another impressive year" - MSN
Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year” - Insider Monkey
Guggenheim Maintains Buy on Eli Lilly (LLY) After "Another Impressive Year" - Finviz
With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec - Fierce Biotech
Eli Lilly's (LLY) Orforglipron Faces New Competition with GPCR's Clinical Data - GuruFocus
Carolyn Bertozzi returns to Lilly board of directors - marketscreener.com
Carolyn Bertozzi to Rejoin Eli Lilly (LLY) Board in December 202 - GuruFocus
Nobel laureate Carolyn Bertozzi returns to Eli Lilly board By Investing.com - Investing.com Canada
Nobel laureate Carolyn Bertozzi rejoins Eli Lilly board - StreetInsider
As Lilly And Novo Nordisk Grow Their Obesity Empires, What Comes Next? - Citeline News & Insights
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term - Yahoo Finance
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump - 24/7 Wall St.
Eli Lilly Says Phase 3 Data Shows Jaypirca Meets Primary Endpoint in Blood, Lymph Node Cancer Trial - marketscreener.com
Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance - International Business Times
Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $1,145 From $951, Maintains Buy Rating - marketscreener.com
Eli Lilly’s Mounjaro to join China’s state health insurance scheme - Investing.com India
Eli Lilly's (LLY) Diabetes Drug Mounjaro Gains Access to China's Insurance Program - GuruFocus
Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog - marketscreener.com
‘A new day’: IU LAB chief talks $40M research agreement with Lilly - Inside INdiana Business
Eli Lilly’s Mounjaro to join China’s state health insurance scheme By Investing.com - Investing.com South Africa
0.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):